Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/rituximab-maintenance-versus-radioimmunotherapy-consolidation-in-FYCcePfR0G
References (64)
-
P. Colombat, N. Brousse, F. Morschhauser, P. Franchi-Rezgui, P. Soubeyran, V. Delwail, E. Deconinck, C. Haioun, C. Foussard, C. Sebban, H. Tilly, N. Milpied, F. Boué, J. Karsenti, P. Lederlin, A. Najman, C. Thieblemont, D. Moreau, L. Bergougnoux, G. Salles, P. Solal-Céligny (2006)
Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.Blood, 108
-
N. Berinstein, A. Grillo‐López, C. White, I. Bence‐Bruckler, D. Maloney, M. Czuczman, D. Green, J. Rosenberg, P. Mclaughlin, D. Shen (1998)
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology, 9 9
-
S. Horning (1993)
Natural history of and therapy for the indolent non-Hodgkin's lymphomas.Seminars in oncology, 20 5 Suppl 5
-
R. Pettengell, N. Schmitz, C. Gisselbrecht, D. Caballero, P. Colombat, E. Conde, B. Metzner, J. Walewski, C. Geisler, A. Goldstone, Marrow Transplantation (2010)
Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy.Journal of Clinical Oncology, 28
-
H. Hochster, E. Weller, R. Gascoyne, T. Ryan, T. Habermann, L. Gordon, S. Frankel, S. Horning (2007)
Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trialJournal of Clinical Oncology, 25
-
L. Vidal, A. Gafter-Gvili, L. Leibovici, M. Dreyling, M. Ghielmini, S. Schmitz, A. Cohen, O. Shpilberg (2010)
Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.Journal of the National Cancer Institute, 101 4
-
C. Foussard, N. Mounier, A. Hoof, V. Delwail, O. Casasnovas, E. Deconinck, H. Tilly, O. Fitoussi, R. Gressin, G. Salles, Gela-Goelams (2006)
Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
S. Gregory, K. Hohloch, C. Gisselbrecht, K. Tobinai, M. Dreyling (2009)
Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.The oncologist, 14 Suppl 2
-
B. Encke, G. Heydecke, Martin Wolkewitz, J. Strub (2009)
Results of a prospective randomized controlled trial of posterior ZrSiO(4)-ceramic crowns.Journal of oral rehabilitation, 36 3
-
K. Ardeshna, W. Qian, Paul Smith, J. Warden, L. Stevens, C. Pocock, F. Miall, D. Cunningham, J. Davies, J. Walewski, A. Ferhanoglu, K. Bradstock, D. Linch (2010)
An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary AnalysisBlood, 116
-
H. Schulz, J. Bohlius, S. Trelle, N. Skoetz, M. Reiser, Thilo Kober, G. Schwarzer, M. Herold, M. Dreyling, M. Hallek, A. Engert (2007)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.Journal of the National Cancer Institute, 99 9
-
T. Witzig, A. Molina, L. Gordon, C. Emmanouilides, R. Schilder, I. Flinn, M. Darif, R. Macklis, K. Vo, G. Wiseman (2007)
Long‐term responses in patients with recurring or refractory B‐cell non‐Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetanCancer, 109
-
E. Grainger (2011)
52nd ASH annual meetingLancet Oncology, 12
-
O. Press, J. Unger, R. Braziel, D. Maloney, T. Miller, M. LeBlanc, R. Fisher (2006)
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 25
-
R. Fisher (2005)
Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma.Clinical advances in hematology & oncology : H&O, 3 7
-
R. Wahl, K. Zasadny, D. MacFarlane, I. Francis, C. Ross, J. Estes, S. Fisher, D. Regan, S. Kroll, M. Kaminski (1998)
Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 39 8 Suppl
-
M. Gordon (2009)
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular LymphomaYearbook of Medicine, 2009
-
G. Salles, J. Seymour, F. Offner, A. López-Guillermo, D. Belada, L. Xerri, P. Feugier, R. Bouabdallah, J. Catalano, P. Brice, D. Caballero, C. Haioun, L. Pedersen, A. Delmer, D. Simpson, S. Leppa, P. Soubeyran, A. Hagenbeek, O. Casasnovas, T. Intragumtornchai, C. Fermé, Maria Silva, C. Sebban, A. Lister, J. Estell, G. Milone, A. Sonet, M. Mendila, B. Coiffier, H. Tilly (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialThe Lancet, 377
-
G. Wiseman, E. Kornmehl, B. Leigh, W. Erwin, D. Podoloff, S. Spies, R. Sparks, M. Stabin, T. Witzig, C. White (2003)
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 44 3
-
M. Oers, R. Klasa, R. Marcus, M. Wolf, E. Kimby, R. Gascoyne, A. Jack, M. Veer, A. Vranovský, H. Holte, M. Glabbeke, I. Teodorović, Cynthia Rozewicz, A. Hagenbeek (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.Blood, 108 10
-
G. Salles, J. Seymour, P. Feugier, F. Offner, A. López-Guillermo, R. Bouabdallah, L. Pedersen, P. Brice, D. Belada, L. Xerri (2010)
Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.Journal of Clinical Oncology, 28
-
P. Mclaughlin, A. Grillo‐López, B. Link, R. Levy, M. Czuczman, M. Williams, M. Heyman, I. Bence‐Bruckler, C. White, F. Cabanillas, V. Jain, A. Ho, J. Lister, K. Wey, D. Shen, B. Dallaire (1998)
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 8
-
L Vidal, A Gafter-Gvili, L Leibovici (2009)
Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trialsJ Natl Cancer Inst., 101
-
M. Kaminski, M. Tuck, J. Estes, A. Kolstad, C. Ross, D. Regan, Thierry Horner, V. Williams, Tina Vleisides, R. Wahl (2009)
Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results.Blood, 114
-
G. Martinelli, S. Schmitz, Urs Utiger, T. Cerny, U. Hess, S. Bassi, E. Okkinga, R. Stupp, R. Stahel, M. Heizmann, D. Vorobiof, A. Lohri, P. Dietrich, E. Zucca, M. Ghielmini (2010)
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 29
-
M Ghielmini, K Rufibach, G Salles (2005)
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)Ann Oncol., 16
-
M. Witzens‐Harig, Monika Reiz, C. Heiss, A. Benner, M. Hensel, K. Neben, P. Dreger, A. Kraemer, A. Ho (2008)
Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trialAnnals of Hematology, 88
-
J. Hainsworth, S. Litchy, H. Burris, D. Scullin, S. Corso, D. Yardley, L. Morrissey, F. Greco (2002)
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 20
-
B. Link, P. Martin, M. Kaminski, S. Goldsmith, M. Coleman, J. Leonard (2010)
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18
-
P McLaughlin, S Neelapu, M Fanale (2008)
R-FND followed by radioimmunotherapy for high-risk follicular lymphoma (abstract)Blood., 112
-
A. Hagenbeek, J. Radford, A. Hoof, U. Vitolo, A. Rohatiner, G. Salles, P. Soubeyran, H. Tilly, A. Delaloye, W. Putten, F. Morschhauser (2010)
90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 PatientsBlood, 116
-
S. Jacobs, S. Swerdlow, J. Kant, K. Foon, R. Jankowitz, S. Land, N. Demonaco, J. Joyce, J. Osborn, T. Evans, P. Schaefer (2008)
Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular LymphomaClinical Cancer Research, 14
-
T. Davis, A. Grillo‐López, C. White, P. Mclaughlin, M. Czuczman, B. Link, D. Maloney, R. Weaver, J. Rosenberg, R. Levy (2000)
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 17
-
F Morschhauser, J Radford, A Hoof (2008)
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaJ Clin Oncol., 26
-
M. Kersten (2011)
Radioimmunotherapy in follicular lymphoma: some like it hot….Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 44 2
-
M. Oers, M. Glabbeke, L. Giurgea, R. Klasa, R. Marcus, M. Wolf, E. Kimby, M. Veer, A. Vranovský, H. Holte, A. Hagenbeek (2010)
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 17
-
F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, A. Delaloye (2009)
Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.The oncologist, 14 Suppl 2
-
R Forstpointner, M Unterhalt, M Dreyling (2006)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Blood., 108
-
E. Kimby, J. Jurlander, C. Geisler, H. Hagberg, H. Holte, T. Lehtinen, Björn Östenstad, M. Hansen, A. Österborg, O. Lindén, C. Sundström, On Group (2008)
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma GroupLeukemia & Lymphoma, 49
-
T. Witzig, P. Fishkin, L. Gordon, S. Gregory, S. Jacobs, R. Macklis, P. Mclaughlin, O. Press, A. Zelenetz (2011)
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference reportLeukemia & Lymphoma, 52
-
R. Fisher (2005)
Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL.Clinical advances in hematology & oncology : H&O, 3 7
-
M. Kaminski, M. Tuck, J. Estes, A. Kolstad, C. Ross, K. Zasadny, D. Regan, P. Kison, S. Fisher, S. Kroll, R. Wahl (2005)
131I-tositumomab therapy as initial treatment for follicular lymphoma.The New England journal of medicine, 352 5
-
M. Herold, A. Haas, S. Srock, S. Neser, K. Al-Ali, A. Neubauer, G. Dölken, R. Naumann, W. Knauf, M. Freund, R. Rohrberg, K. Höffken, A. Franke, T. Ittel, E. Kettner, U. Haak, U. Mey, C. Klinkenstein, M. Assmann, U. Grünhagen (2007)
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 15
-
H. Hochster, E. Weller, R. Gascoyne, T. Habermann, L. Gordon, T. Ryan, Lijun Zhang, N. Colocci, S. Frankel, S. Horning (2009)
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 10
-
H Schulz, JF Bohlius, S Trelle (2007)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisJ Natl Cancer Inst., 99
-
P. Zinzani, M. Tani, A. Pulsoni, M. Gobbi, A. Perotti, S. Luca, A. Fabbri, A. Zaccaria, M. Voso, P. Fattori, L. Guardigni, S. Ronconi, M. Cabras, L. Rigacci, A. Renzo, E. Marchi, V. Stefoni, M. Fina, C. Pellegrini, G. Musuraca, E. Derenzini, S. Pileri, S. Fanti, P. Piccaluga, M. Baccarani (2008)
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).The Lancet. Oncology, 9 4
-
M. Czuczman, C. Emmanouilides, M. Darif, T. Witzig, L. Gordon, S. Revell, K. Vo, A. Molina (2007)
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 27
-
L. Aledort, R. Lyons, G. Okano, J. Leveque (2006)
Retrospective Matched Cohort Study of Immune Thrombocytopenic Purpura (ITP): Complications Related to Corticosteroid (CS) Use.Blood, 108
-
S. Hilchey, O. Hyrien, T. Mosmann, A. Livingstone, J. Friedberg, F. Young, R. Fisher, R. Kelleher, R. Bankert, S. Bernstein (2009)
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.Blood, 113 16
-
R. Fisher, M. Kaminski, R. Wahl, S. Knox, A. Zelenetz, J. Vose, J. Leonard, S. Kroll, S. Goldsmith, M. Coleman (2005)
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 30
-
M. Dreyling, R. Forstpointner, H. Boeck, R. Repp, H. Wandt, C. Pott, J. Seymour, B. Metzner, A. Haenel, Tanja Lehmann, F. Hartmann, H. Einsele, M. Unterhalt, W. Hiddemann (2006)
Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.Blood, 108
-
L. Gordan, William Grow, A. Pusateri, Vonda Douglas, N. Mendenhall, J. Lynch (2005)
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 6
-
J. Hainsworth, S. Litchy, Don Shaffer, V. Lackey, M. Grimaldi, F. Greco (2005)
Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 6
-
W Hiddemann, M Kneba, M Dreyling (2005)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood., 106
-
M. Dreyling, L. Trümper, C. Schilling, M. Rummel, U. Holtkamp, A. Waldmann, J. Wehmeyer, M. Freund (2007)
Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma—role of radioimmunotherapyAnnals of Hematology, 86
-
D. Mehta, R. Jankowitz, D. Lenzner, S. Land, S. Jacobs (2010)
Phase II study of short course CHOP-rituximab followed by 90-y ibritumomab tiuxetan as first-line treatment for follicular lymphoma: Extended follow-up and predictors of relapse.Journal of Clinical Oncology, 28
-
J. Friedberg (2011)
Rituximab maintenance in follicular lymphoma: PRIMAThe Lancet, 377
-
B. Kahl (2006)
Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT).Clinical lymphoma & myeloma, 6 5
-
P. Mclaughlin, S. Neelapu, M. Fanale, M. Rodriguez, A. Ayala, B. Pro, F. Hagemeister, A. Younes, Susan Neel, N. Fowler, M. Hess, L. Kwak (2008)
R-FND Followed by Radioimmunotherapy for High-Risk Follicular LymphomaBlood, 112
-
P. Zinzani, M. Tani, A. Broccoli, E. Derenzini, A. Pulsoni, A. Renzo, S. Fanti, M. Fina, L. Gandolfi, C. Pellegrini, V. Stefoni, M. Baccarani (2009)
A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients.Blood, 114
-
J. Hainsworth, D. Spigel, T. Markus, D. Shipley, D. Thompson, R. Rotman, C. Dannaher, F. Greco (2009)
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.Clinical lymphoma & myeloma, 9 3
-
R Forstpointner, M Dreyling, R Repp (2004)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood., 104
-
R. Marcus, K. Imrie, A. Belch, D. Cunningham, E. Flores, J. Catalano, P. Solal-Céligny, F. Offner, J. Walewski, J. Raposo, A. Jack, Paul Smith (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.Blood, 105 4
-
M. Ghielmini, S. Schmitz, S. Cogliatti, G. Pichert, J. Hummerjohann, Ursula Waltzer, M. Fey, D. Betticher, G. Martinelli, F. Peccatori, U. Hess, E. Zucca, R. Stupp, T. Kovacsovics, C. Helg, A. Lohri, M. Bargetzi, D. Vorobiof, T. Cerny (2004)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.Blood, 103 12
- Publisher
- Springer Journals
- Copyright
- Copyright © 2011 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Geriatrics/Gerontology; Oncology; Hematology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-011-0099-5
- pmid
- 21909660
- Publisher site
- See Article on Publisher Site
Abstract
Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include prolongation of survival and effective palliation of symptoms while limiting the duration of therapy to minimize adverse effects and reduce costs. Multiple rounds of treatment over many years characterize the clinical course for most patients with FL. Rituximab in combination with chemotherapy has been shown to improve overall survival in patients with FL compared with chemotherapy alone. Rituximab maintenance further improves disease control in patients with FL after a successful induction therapy in both first-line treatment and relapse. Consolidation with radioimmunotherapy is an innovative treatment approach to increase rates of complete remission and duration of remission. Here we summarize the data from actual trials and the resulting treatment indications.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Sep 10, 2011